Zobrazeno 1 - 10
of 56
pro vyhledávání: '"E. E. Voest"'
Autor:
J. M. van Berge Henegouwen, H. van der Wijngaart, L. J. Zeverijn, L. R. Hoes, M. Meertens, A. D. R. Huitema, L. A. Devriese, M. Labots, H. M. W. Verheul, E. E. Voest, H. Gelderblom
Publikováno v:
Cancer Chemotherapy and Pharmacology, 90(1), 97-104. Springer Verlag
Cancer Chemotherapy and Pharmacology, 90(1), 97-104. SPRINGER
van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, Hoes, L R, Meertens, M, Huitema, A D R, Devriese, L A, Labots, M, Verheul, H M W, Voest, E E & Gelderblom, H 2022, ' Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer : a case series and review of literature ', Cancer Chemotherapy and Pharmacology, vol. 90, no. 1, pp. 97-104 . https://doi.org/10.1007/s00280-022-04437-z
Cancer Chemotherapy and Pharmacology, 90(1), 97-104. SPRINGER
van Berge Henegouwen, J M, van der Wijngaart, H, Zeverijn, L J, Hoes, L R, Meertens, M, Huitema, A D R, Devriese, L A, Labots, M, Verheul, H M W, Voest, E E & Gelderblom, H 2022, ' Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer : a case series and review of literature ', Cancer Chemotherapy and Pharmacology, vol. 90, no. 1, pp. 97-104 . https://doi.org/10.1007/s00280-022-04437-z
Introduction The combination of vemurafenib, a proto-oncogene B-Raf inhibitor (BRAFi) and cobimetinib, an inhibitor of mitogen-activated protein kinase kinase (MEKi) has shown to improve survival in patients with BRAF V600-mutated melanoma. BRAF muta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cb239b7fd18bf5826e94d10bb3a976a
https://research.vumc.nl/en/publications/bc9073e0-357d-4439-b7d7-5165678c433e
https://research.vumc.nl/en/publications/bc9073e0-357d-4439-b7d7-5165678c433e
Autor:
P. Kaur, Hilde Rosing, Frederik E. Stuurman, Jos H. Beijnen, E. E. Voest, L. Rolfe, Jan H.M. Schellens, Martijn P. Lolkema, Patricia M. M. B. Soetekouw, H. van Tinteren, Alwin D. R. Huitema
Publikováno v:
The Journal of Clinical Pharmacology. 53:878-883
Autor:
D. S. Chen, D. M. Feltquate, F. Smothers, A. Hoos, S. Langermann, S. Marshall, R. May, M. Fleming, F. S. Hodi, A. Senderowicz, K. G. Wiman, S. de Dosso, W. Fiedler, L. Gianni, S. Cresta, H. B. Schulze-Bergkamen, L. Gurrieri, M. Salzberg, B. Dietrich, A. Danielczyk, H. Baumeister, S. Goletz, C. Sessa, D. Strumberg, B. Schultheis, A. Santel, F. Gebhardt, W. Meyer-Sabellek, O. Keil, K. Giese, J. Kaufmann, M. Maio, G. Choy, A. Covre, G. Parisi, H. Nicolay, E. Fratta, E. Fonsatti, L. Sigalotti, S. Coral, P. Taverna, M. Azab, E. Deutsch, C. Lepechoux, J. P. Pignon, Y. T. Tao, S. Rivera, B. C. Bourgier, M. Angokai, R. Bahleda, K. Slimane, E. Angevin, B. B. Besse, J. C. Soria, K. Dragnev, J. H. Beumer, B. Anyang, T. Ma, F. Galimberti, C. P. Erkmen, W. Nugent, J. Rigas, K. Abraham, D. Johnstone, V. Memoli, E. Dmitrovsky, E. E. Voest, L. Siu, F. Janku, A. Tsimberidou, R. Kurzrock, J. Tabernero, J. Rodon, R. Berger, A. Onn, G. Batist, C. Bresson, V. Lazar, J. J. Molenaar, J. Koster, M. Ebus, D. A. Zwijnenburg, P. van Sluis, F. Lamers, L. Schild, I. van der Ploeg, H. N. Caron, R. Versteeg, J. Pouyssegur, I. Marchiq, J. Chiche, D. Roux, R. Le Floch, S. E. Critchlow, R. F. Wooster, S. Agresta, K. E. Yen, P. A. Janne, E. R. Plummer, G. Trinchieri, L. Ellis, S. L. Chan, W. Yeo, A. T. Chan, F. Mouliere, S. El Messaoudi, C. Gongora, P. J. Lamy, M. del Rio, E. Lopez-Crapez, B. Gillet, M. Mathonnet, D. Pezet, M. Ychou, A. R. Thierry, V. Ribrag, W. Vainchenker, S. Constantinescu, H. Keilhack, I. A. Umelo, A. Noeparast, G. Chen, M. Renard, C. Geers, J. Vansteenkiste, E. Teugels, J. de Greve, O. Rixe, X. Qi, Z. Chu, J. Celerier, L. Leconte, N. Minet, J. Pakradouni, B. Kaur, F. Cuttitta, A. J. Wagner, Y. X. Zhang, E. Sicinska, J. T. Czaplinski, S. P. Remillard, G. D. Demetri, S. Weng, L. Debussche, L. Agoni, E. P. Reddy, C. Guha, K. Silence, A. Thibault, H. de Haard, T. Dreier, P. Ulrichts, M. Moshir, S. Gabriels, J. Luo, C. Carter, A. Rajan, S. Khozin, A. Thomas, A. Lopez-Chavez, C. Brzezniak, L. Doyle, C. Keen, M. Manu, M. Raffeld, G. Giaccone, S. Lutzker, J. M. Melief, S. G. Eckhardt, L. Trusolino, G. Migliardi, E. R. Zanella, F. Cottino, F. Galimi, F. Sassi, S. Marsoni, P. M. Comoglio, A. Bertotti, M. Hidalgo, S. J. Weroha, P. Haluska, M. A. Becker, S. C. Harrington, K. M. Goodman, S. E. Gonzalez, M. al Hilli, K. A. Butler, K. R. Kalli, A. L. Oberg, I. J. Huijbers, R. Bin Ali, C. Pritchard, M. Cozijnsen, N. Proost, J. Y. Song, P. Krimpenfort, E. Michalak, J. Jonkers, A. Berns, U. Banerji, A. Stewart, P. Thavasu, S. Banerjee, S. B. Kaye
Publikováno v:
Annals of Oncology. 24:i7-i17
Autor:
Bernard A. Zonnenberg, P. Quarles van Ufford-Mannesse, de Margriet Vries, Thera P. Links, E. E. Voest, J. W. B. de Groot, Cornelis J.M. Lips
Publikováno v:
Journal of Clinical Endocrinology and Metabolism, 92(9), 3466-3469. ENDOCRINE SOC
Context: Medullary thyroid carcinoma (MTC) metastasizes early in its clinical course. No effective systemic therapy is available. Generally (somatic or germline), mutations in the rearranged during transfection gene are considered essential in the pa
Publikováno v:
International Journal of Gynecological Cancer. 16:65-70
Verhaar-Langereis M, Karakus A, van Eijkeren M, Voest E, Witteveen E. Phase II study of the combination of pegylated liposomal doxorubicin and topotecan in platinum-resistant ovarian cancer. Int J Gynecol Cancer 2006;16:65–70. The combination of li
Publikováno v:
Clinical Otolaryngology and Allied Sciences. 29:729-734
Several randomized studies and meta-analyses have shown that simultaneous radio- and chemotherapy prolongs survival in patients with unresectable squamous cell carcinoma of the head and neck as compared with conventional radiotherapy. We assessed the
Autor:
J. Van Gorp, E. A. te Velde, E. E. Voest, J. M. Vogten, M. F. G. B. Gebbink, I. H. M. Borel Rinkes
Publikováno v:
British Journal of Surgery. 89:1302-1309
Background Tumour-induced microvascular networks have become attractive targets in cancer therapy. Strategies that target both tumour cells and vasculature have not been investigated in models of early metastatic colorectal disease. The efficacy of a
Autor:
F E, Stuurman, M P, Lolkema, A D R, Huitema, P M M B, Soetekouw, H, Rosing, L, Rolfe, P, Kaur, J H, Beijnen, H, van Tinteren, E E, Voest, J H M, Schellens
Publikováno v:
Journal of clinical pharmacology. 53(8)
Publikováno v:
European Respiratory Journal. 8:1389-1397
For patients with non-small cell lung cancer the tumour/node/metastasis (TNM) staging system and other conventional prognostic factors fail to predict the outcome of treatment and survival accurately. New prognostic factors are urgently needed to imp
Autor:
J.P. Neijt, A. W. Dekker, J.W.R. Nortier, J. E. E. Keunen, B. S. Van Asbeck, F. E. Ros, E. E. Voest, J. J. M. Marx
Publikováno v:
Cancer Chemotherapy and Pharmacology. 31:357-362
A novel approach to enhance the activity of doxorubicin is to increase the availability of cellular "chelatable" iron to participate in doxorubicin-mediated free-radical generation. To achieve this, we designed a regimen consisting of desferrioxamine